SELDI-TOF Analysis of Prostate Cancer Proteins in Sera of Hispanic Patients-pilot

前列腺癌(PCA)是美国男性癌症相关死亡的第二大原因。无论疾病处于哪个阶段，西班牙裔患者的五年相对存活率似乎都低于非西班牙裔白人。长期目标是确定与疾病进展相关的新的分子标记。目前临床上使用的肿瘤标记物的特异性和预测价值都很低。新技术可用于 蛋白质组的分析和当前用于分析前列腺基因组的技术为识别在前列腺癌早期和晚期选择性表达的蛋白质及其基因打开了新的窗口。最近的一些研究表明，高加索人和非裔美国人的血清中表达不同的蛋白质模式 前列腺癌患者。在一个有很强拉美裔遗传的人群中，还没有进行过广泛的研究。我们假设，在西班牙裔人群中，不同的蛋白质组表达是分期进展和生存差异的基础。在这项拟议的研究中，将使用蛋白质组学方法对波多黎各的健康和前列腺癌拉美裔患者进行检查。我们的第一个目标是在诊断时和治疗前在这些患者的血清中建立蛋白质模式。该方法将结合使用Surface 增强激光解吸电离(SELDI)比较健康患者和新诊断的未经治疗的前列腺癌患者的蛋白质表达模式，并与已发表的其他种族人群的结果进行比较。15名健康人和20名前列腺癌患者的蛋白质模式将在基线时进行分析。将测试发现的模式的预测性 使用另外25个盲样本值。我们的第二个目标是利用凝胶蛋白分解、蛋白质测序和等电聚焦来表征前列腺癌中表达改变的丰富蛋白质种类。在第三个目标中，我们将把蛋白质模式的变化与疾病的发展阶段联系起来。血清样本分析将在该项目的第1-4年进行，以分析可能与进展相关的模式变化。在 在本项目的背景下，这些相关性的结果可以作为更广泛的研究的基础，以寻找预测标记物来将患者分配到特定的治疗方案。这项研究将进一步了解拉美裔美国人前列腺癌发生的潜在变化。该项目还将提供机会，增加少数民族、训练有素的临床研究人员的数量，并促进西班牙裔人进入临床。 研究。

Prostate cancer (PCa) is the second leading cause of cancer related deaths among males in the United States. Hispanic patients seem to have a lower five year relative survival rate regardless of the stage of disease than white non Hispanic. The long term goal is to identify new molecular markers related to progression of the disease. Current tumor markers in use in the clinical setting have been shown to have low specificity and low predictive value. New technologies for the analysis of the proteome and current technologies for the analysis of the genome of the prostate gland open a new window for identifying proteins and their genes that may selectively express during the early and late stages of prostate (PCa). Recently some studies have suggested distinct protein patterns expressed in the serum of Caucasian and African-American prostate cancer patients. No broad study has been done in a population with a strong Hispanic imheritance. We hypothesize that distinct proteome expression underlies the difference in stage progression and survival in the Hispanic population. In the proposed research a proteomics approach will be used in the examination of healthy and prostate cancer Hispanic patients in Puerto Rico. Our first aim is to establish protein patterns in the sera of these patients at the time of diagnosis and before any treatment. The methodology will incorporate the use of Surface Enhanced Laser Desorption Ionization (SELDI) to compare the patterns of protein expression in healthy patients and in newly diagnosed untreated PCa patients and compare them with published results for other ethnic populations. Protein patterns for 15 healthy and 20 PCa patients will be analyzed at baseline. Patterns found will be tested for their predictive value using an additional 25 blinded samples. Our second aim is the characterization of abundant protein species with altered expression in prostate cancer using gel proteolysis and protein sequencing and isoelectric focusing. In aim three we will correlate changes in protein patterns with stages of progression of the disease. Sera sample analysis will be performed through years 1-4 of this project to assay for changes in pattern that may correlate to progression. In the context of this project, results from these correlations may serve as the base for a broader study to find predictive markers to assign patients to specific therapies. This research will provide further understanding of the changes underlying the development of prostate cancer in Hispanics. This project will also provide the opportunity to increase the number of ethnic minority, trained clinical researchers and facilitate the recruitment of Hispanies into clinical research.